The Serum Institute of India (SII) expects to soon receive World Health Organisation (WHO) emergency use authorisation for the Oxford University/AstraZeneca Covid-19 vaccine, produced for mid and low-income countries.
Reuters quoted SII chief executive Adar Poonawalla as saying at the Reuters Next conference: “The emergency use licensure from the WHO should be available and coming through in the next week or two, hopefully, because we have submitted everything.”
Poonawalla added that SII was aiming to initiate deliveries of the WHO-backed COVAX initiative by this month-end.
A single dose of the vaccine will cost $3 for low-income countries and sold to others at a ‘slightly higher’ rate.
The vaccine maker already sold 11 million doses to the Indian government, which is planning to initiate the world’s largest mass vaccination campaign on 16 January.
Indian Prime Minister Narendra Modi will launch the rollout of the drive at a total of 3,006 session sites virtually.
In the first phase, the country intends to vaccinate around 300 million people.
Earlier this month, the Drugs Controller General of India (DCGI) approved Covid-19 vaccines of Serum Institute of India (SII) and Bharat Biotech for restricted use in emergency situations.
Meanwhile, Brazil is sending an aircraft to India to carry the first two million Covid-19 vaccine doses supplied by SII. The Brazilian government’s Fiocruz biomedical institute secured the doses.
In a separate development, the US Food and Drug Administration (FDA) granted Fast Track designation to Innovation Pharmaceuticals’ Brilacidin for the treatment of patients with Covid-19.
A Host Defense Protein (HDP) mimetic, Brilacidin has antiviral, anti-inflammatory and antibacterial properties.
by Pharmaceutical-Technology.com
Source: pharmaceutical-technology.com
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
